PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Wet AMD - Market size and forecast 2018-2023 Dry AMD - Market size and forecast 2018-2023 Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Strategic alliances Development of gene therapy for AMD Growing awareness about AMD PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Amgen Inc. Bausch Health Companies Inc. F. Hoffmann-La Roche Ltd. Novartis AG Regeneron Pharmaceuticals Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Type - Market share 2018-2023 (%) Exhibit 18: Comparison by type Exhibit 19: Wet AMD - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Wet AMD - Year-over-year growth 2019-2023 (%) Exhibit 21: Dry AMD - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Phase III drugs for dry AMD Exhibit 23: Cell therapies under development for dry AMD Exhibit 24: Dry AMD - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by type Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Top 3 countries in North America Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in Europe Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Population aged 65 years and above (% of total) in Asia 2017 Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Some late-stage drugs for treatment of AMD Exhibit 45: Global growth in geriatric population 2013-2017 (%) Exhibit 46: Approximate cost of AMD drugs Exhibit 47: Companies developing biosimilars: Overview Exhibit 48: Side effects associated with drugs used for AMD Exhibit 49: Impact of drivers and challenges Exhibit 50: Vendor landscape Exhibit 51: Landscape disruption Exhibit 52: Vendors covered Exhibit 53: Vendor classification Exhibit 54: Market positioning of vendors Exhibit 55: Amgen Inc. - Vendor overview Exhibit 56: Amgen Inc. - Business segments Exhibit 57: Amgen Inc. - Organizational developments Exhibit 58: Amgen Inc. - Geographic focus Exhibit 59: Amgen Inc. - Key offerings Exhibit 60: Amgen Inc. - Key customers Exhibit 61: Bausch Health Companies Inc. - Vendor overview Exhibit 62: Bausch Health Companies Inc. - Business segments Exhibit 63: Bausch Health Companies Inc. - Organizational developments Exhibit 64: Bausch Health Companies Inc. - Geographic focus Exhibit 65: Bausch Health Companies Inc. - Segment focus Exhibit 66: Bausch Health Companies Inc. - Key offerings Exhibit 67: Bausch Health Companies Inc. - Key customers Exhibit 68: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 69: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 70: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 71: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 72: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 73: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 74: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 75: Novartis AG - Vendor overview Exhibit 76: Novartis AG - Business segments Exhibit 77: Novartis AG - Organizational developments Exhibit 78: Novartis AG - Geographic focus Exhibit 79: Novartis AG - Segment focus Exhibit 80: Novartis AG - Key offerings Exhibit 81: Novartis AG - Key customers Exhibit 82: Regeneron Pharmaceuticals Inc. - Vendor overview Exhibit 83: Regeneron Pharmaceuticals Inc. - Business segments Exhibit 84: Regeneron Pharmaceuticals Inc. - Organizational developments Exhibit 85: Regeneron Pharmaceuticals Inc. - Geographic focus Exhibit 86: Regeneron Pharmaceuticals Inc. - Key offerings Exhibit 87: Regeneron Pharmaceuticals Inc. - Key customers Exhibit 88: Validation techniques employed for market sizing Exhibit 89: Definition of market positioning of vendors

Amgen Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc.